[Dysarthria?].
Ozsancak
C
C
Service de Neurologie et Pathologie du Mouvement, Hôpital Roger Salengro, CHRU de Lille, Lille.
Auzou
P
P
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004401:Dysarthria / Q000145:classification / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D006801:Humans; D007806:Language Disorders / Q000175:diagnosis; D007818:Laryngeal Diseases / Q000150:complications; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy; D009422:Nervous System Diseases / Q000150:complications; D009468:Neuromuscular Diseases / Q000150:complications; D019635:Neurosurgical Procedures; D013065:Speech Intelligibility; D013068:Speech Production Measurement; D020521:Stroke / Q000150:complications
D002800:Cholinesterase Inhibitors; D019274:Botulinum Toxins, Type A